cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of fESWT in the Treatment of CTS

The carpal tunnel syndrome (CTS) is the most common entrapment neuropathy in the general population.The focus extracorporeal shock wave (fEWST) is a non invasive treatment for various diseases. FESWT is new and potential treatment for peripheral nerve entrapment/ peripheral neuropathy . But there is still little known about the effects and long term effects of fESWT in the treatment of CTS.

The aim of this study is to determine the effectiveness of fESWT in patients with carpal tunnel syndrome compared to participants receiving only night splint. Therefore 40 patients with mild to moderate CTS (verified by nerve conduction velocity) will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.

Evaluation will be performed at baseline (VAS, hand grip, electrodiagnostic parameters, questionnaires), 3 weeks (VAS, hand grip, questionnaires), 12 and 24 weeks (VAS, hand grip, electrodiagnostic parameters, questionnaires) after treatment.

Eligibility Criteria:
Inclusion Criteria:

- mild to moderate CTS verified by nerve conduction velocity

Exclusion Criteria:

* metabolic diseases
* blood clotting problems
* systemic diseases
* polyneuropathy
* chemotherapy during the study
* corticosteroid therapy
* use of anticoagulation
* history of trauma/surgery or nerve lesion of the teated extremity
* CTS surgery on the affected hand
* ICD/ pacemaker implantation
* other therapy for the affected hand during the study
* acute inflammation or infections
* severe mental illnesses/psychiatric diseases
* severe neurological diseases
A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

A medical review chart study in Japan to describe the treatment patterns and outcomes of patients with kidney cancer that is unable to be removed by surgery or that has spread. The clinical data is to be abstracted using electronic data capture (eDC) from patient medical records in Japan.


Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* Adults 20 years and older at the time of initial diagnosis of mRCC
* Alive or deceased as of the date of data collection
* Diagnosis of mRCC between 01-Jan-2012 and 31-Aug-2015

Exclusion Criteria:

* Previously and/or currently enrolled in RCC clinical trials
* Patients have primary cancer other than renal cell cancer
Treatment of Chronic Bacterial Prostatitis

Background - bacterial prostatitis (BP) is a common condition accounting responsible for about 5-10% of all prostatitis cases; chronic bacterial prostatitis (CBP) classified as type II, are less common but is a condition that significantly hampers the quality of life, (QoL) because not only is it a physical condition but also a psychological distress. Commonly patients are treated with antibiotics alone, and in particular fluoroquinolones are suggested by the European Urology guidelines. This approach, although recommended, may not be enough. Thus, a multimodal approach to the prolonged antibiotic therapy may be helpful.

Methods - 210 patients affected by chronic bacterial prostatitis were enrolled in the study. All patients were positive to Meares-Stamey test and symptoms duration was \> 3 months. The purpose of the study was to evaluate the efficacy of a long lasting therapy with a fluoroquinolone in association with a nutraceutical supplement (prulifloxacin 600 mg for 21 days and an association of Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg for 30 days). Patients were randomized in two groups (A and B) receiving respectively antibiotic alone and an association of antibiotic plus supplement.


Eligibility Criteria:
Inclusion Criteria:

* patients affected by chronic bacterial prostatitis
* positivity to the Meares-Stamey test
* symptoms duration \> 3 months (dysuria, pelvic pain and/or discomfort)

Exclusion Criteria:

* positivity to Chlamydia trachomatis, Ureaplasma urealiticum, Mycoplasma, Neisseria gonorrhoeae, herpes simplex viruses (HSV 1/2) and human papillomavirus (HPV)
* age less than 18 years
* history of neurological disease, urinary stones or cancer
* allergy to fluoroquinolones
* refusal to sign the informed consent
* incomplete follow-up time.
Engagement in HIV Primary Care Services

This study is to look at things that may affect whether or not people who are HIV-infected get into medical care and stay in medical care. some of the things that will be examined include how drug use, HIV disease severity, mental health, housing, trust, feelings of discrimination, social support, relationship with provider, and patient's race and provider's race are linked with whether or not people get health care. People who are enrolled in the study will be interviewed once, and their medical records will be examined.

The purpose of this study is to understand the determinants of entry and engagement in HIV primary care services for Blacks and Hispanics living in single room occupancy (SRO) hotels in Bronx and Manhattan, NY. More specifically, the goal is to examine baseline cultural characteristics of the patient, health-related characteristics of the patient, the patient-provider relationship, and the impact of community outreach on engagement in health care. The objectives are to: examine the association between trust, relationship with provider, social support, and health beliefs with engagement in HIV primary care services; examine the association between health-related characteristics and engagement in HIV primary care services; examine the association of perceived cultural concordance between provider and patient with engagement in HIV primary care services; and, explore the relationship between community outreach and entry into HIV primary care services.

We will be recruiting a convenience sample of 500 Black or Hispanic HIV-infected adults living in 14 SRO hotels (transitional emergency housing) in the Bronx and Manhattan, NY. We will be conducting interviews through auditory computer-assisted self-interviewing (A-CASI) technology, using standardized research instruments administered in English or Spanish. We will also be reviewing medical charts and records from Citiwide and Montefiore appointment databases.

Understanding barriers to engagement in HIV primary care will lead to development of culturally relevant interventions to assist Black and Hispanic persons in entering and engaging in HIV treatment. Implementation of these interventions will ultimately help reduce disparities in HIV-related healthcare, as well as reduce HIV morbidity and mortality in Black and Hispanic populations.

Eligibility Criteria:
Inclusion Criteria:

* at least 18 years of age, HIV-infected, living in one of 15 different single room occupancy hotels in New York City, English or Spanish speaking

Exclusion Criteria:

* HIV-negative
Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier

The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant woman over 18 years old
* Woman whose gestational age is less than 30 weeks.
* Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks
* Give birth in the inclusion center
* Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status
* Affiliated with the Social Security system

Exclusion Criteria:

* Patient who underwent a blood transfusion less than 2 months ago
* Patient who received an organ transplant
* Patient undergoing immunotherapy, stem cell therapy and/or other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion
High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure

The primary objective of this pilot trial is to determine whether inpatients presenting to the Emergency Department (ED) with symptoms suggestive of Acute Heart Failure (AHF), who receive supplemental oxygen adjusted at either a high (SpO2 range ≥96%) or low (SpO2 range 90-92%) oxygen saturation level, leads to greater reduction in N-terminal-proBNP (NT-proBNP) at 72 hours.

Patients will be randomized to either a high (SpO2 range ≥96%) or low (SpO2 range 90-92%) oxygen after informed consent.

Eligibility Criteria:
Inclusion Criteria:

* \>40 years of age presenting to the ED with AHF
* objective finding of HF (BNP \>400 pg/ml or Chest X-Ray with pulmonary congestion)
* plan to admit with primary diagnosis as HF
* must be able to be randomized within 16 hours of presenting to the ED
* provided written informed consent

Exclusion Criteria:

* on home oxygen
* known prior hypercapnic failure (PaCO2 \>50 mmHg)
* asthma
* primary pulmonary hypertension,
* patients who require urgent positive pressure ventilation or intubation
* patients on \>10 L/min oxygen
Resuscitation Decisions in the Emergency Department (ED)

The investigators will retrospectively examine the connection between resuscitation decisions of admitted patients at the ED of the University Hospital of Basel and several demographic and health related measures. Additionally there will be an examination, which patient characterestics may have lead to patients not having been asked about resuscitation decisions.


Eligibility Criteria:
Inclusion Criteria:

* Patients admitted to the emergency department (duration of hospitalisation more than 24 h).
* Patients with a research consent "yes".

Exclusion Criteria:

* Patients being discharged within less than 24 hours.
* Patients with a research consent "no".
Computer Guided Versus Free Hand Horizontal Ridge Augmentation in Anterior Mandible.

Assessment of horizontal ridge augmentation in anterior mandible using computer guided autogenous cortical shell technique versus free hand technique:

randomized clinical trial

patients with deficient anterior mandible were included in this study where control group patients received free hand harvesting and fixation of cortical shells from the symphysis, while the study group patients received the same protocol using 2 patient specific guides (psg) the first guide used for safe and accurate graft harvesting with the proposed dimensions while the second guide used for shell fixation leaving the desired gap with the recipient site that was filled with a particulate mix of xeno and auto grafts .the first guide was fixed in place allowing for accurate harvesting of the cortical shell of desired dimensions from the symphysis Then; the harvested shell was fixed to the second guide outside the patients mouth using micro screws And this fixation guide was finally secured to its final position using two interlocking wings to lock into the first guide at the surgical site as a verification step for the accuracy of the whole procedure. Finally, the 2 guides were removed after shell fixation to the recipient site in a through and through manner st the proposed planed position.

Eligibility Criteria:
Inclusion Criteria:

* • Age ranges from 25-55 years. No sex predilection.

  * Patients free from any systemic conditions and bone metabolism diseases that might interfere with the surgical intervention, soft tissue or hard tissue healing.
  * Edentulous anterior mandible with horizontally deficient alveolar ridge that is less than 3mm width.
  * Normal vertical dimension with normal inter-arch space.
  * The minimum number of missing teeth in the anterior mandible alveolar ridge is two adjacent teeth.

Exclusion Criteria:

* • Intra-bony lesions (e.g., cysts) or infections (e.g., abscess) that may retard the osteotomy healing.

  * Previous grafting procedures in the edentulous area.
Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks.

Secondary objectives are:

* To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL-cholesterol and visceral fat area.
* To evaluate the safety of SR141716 compared to placebo over a period of 104 weeks.
* To evaluate the pharmacokinetics of SR141716.


Eligibility Criteria:
Inclusion Criteria:

* Body Mass Index (BMI) \> 25 kg/m²
* Visceral Fat Area (VFA) \> 100 cm²
* Triglycerides (TG) \> 150 mg/dL and \< 700 mg/dL, and/or HDL-cholesterol \< 40 mg/dL(Dyslipidemia)
* At least 1 criteria of the following 2 comorbidities:

  * Impaired Glucose Tolerance or Type 2 diabetes
  * Hypertension

Exclusion Criteria:

* Patient with a secondary obesity.
* Patients who have received the diet therapy for less than 8 weeks before start of the observation period.
* Patients whose body weight changed by more than the variation of ± 2kg for screening period.
* Low compliance to drug intake (\< 80%) and dietary instruction during the observation period.
* Patients with type 1 diabetes.
* Patients with a primary hyperlipidemia (i.e., familial hypercholesterolemia, familial combined hyperlipidemia and familial type III hyperlipidemia).
* Patients with a LDL-cholesterol \> 190 mg/dL at any of Weeks -8 or -4.
* Patients with a secondary hypertension.
A Study to Test How Different Doses of BI 1015550 Are Taken up in the Body of Healthy Japanese Men

The main objectives of this trial are to investigate pharmacokinetics (PK) of R-BI 1015550 in Japanese healthy male subjects following oral administration of two different single BI 1015550 doses.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR), Respiratory rate (RR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
* Age of 18 to 45 years (inclusive)
* Body mass index (BMI) of 18.5 to 25 kg/m2 (inclusive)
* Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

Exclusion Criteria:

* Any finding in the medical examination (including BP, PR, RR or ECG) deviating from normal and assessed as clinically relevant by the investigator
* Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 40 to 90 mmHg, or PR outside the range of 40 to 99 beats per minute (bpm)
* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
* Any evidence of a concomitant disease assessed as clinically relevant by the investigator
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
* Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
* Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
* History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Malignant Pediatric Pelvic Tumors: A Retrospective Study

The aim of the study is to retrospectively review data about malignancies that arise primarily in the pelvis and/or in the pelvic organs, in pediatric cancer patients \& categorize the spectrum of these malignancies according to experience at South Egypt Cancer Institute which is the largest referral site in Upper Egypt.

Background:

The newborn and infant pelvis is not fully developed and the bladder, uterus, and ovaries are to a large degree intra-abdominal. The pelvis of the infant and child has different anatomic relationships than the adolescent or adult pelvis. Neoplasms of the pediatric pelvis constitute a unique group requiring highly specialized management in a setting staffed by pediatric surgical and radiation oncologists. The most common neoplasms are rhabdomyosarcomas of the bladder, prostate, and vagina; sacrococcygeal teratoma; and the germ cell tumors, including teratomas, endodermal sinus tumors, and the choriocarcinomas. Rapidly improving chemotherapy for all of these lesions has resulted in a changed role for the surgeon.

Patients \& Methods:

A hospital-based study, involving Pediatric cancer patients, those have been diagnosed with malignant tumors that primarily arising in the pelvis and/or arising from the pelvic organs, and may have an intra-abdominal extension, in the period from 2001 January till 2015 December, and received treatment at the pediatric oncology department, their medical reports will be retrospectively reviewed for data collection.

Spectrum of these malignancies will be categorized and recorded as specific disease entities, based on morphology \& the primary site of occurrence, their relative incidence will be calculated, and the treatment outcomes will be verified.

Eligibility Criteria:
Inclusion Criteria:

* Patients whose age less than 19 years.
* Patients diagnosed with a primary malignant tumor in the pelvis and/or arising from the pelvic organs.

Exclusion Criteria:

* Patients whose age more than 18 years.
* Patients diagnosed with a malignant disease primarily arising from the bone marrow.
Quality of Life and Health Perception After Surgery of Varicose Veins

The aim of this study is to analyze changes in health perception and quality of life in patients after surgery for varicose veins using clinical score VCSS and QoL scores SF12 as general health questionary and Veines QoL/Sym as disease specific questionary.


Eligibility Criteria:
Inclusion Criteria:

* patients with reflux in saphenous vein

Exclusion Criteria:

* no reflux in saphenous vein
Effect of Synbiotic on Postoperative Complications After Liver Transplantation

The purpose of this study is to evaluate the use of synbiotic in patients after liver transplantation and assess the effect of these agents on postoperative infections, antibiotic use, length of hospital stay, mortality and nutritional status.

All patients who are undergoing liver transplantation at the Hospital de Clinicas de Porto Alegre over the next 18 months will be informed of the purpose of the study. The patients or their legal guardians provided will written an informed consent for participation at the study.

The patients will be allocated to the intervention or control groups by randomization in blocks. The intervention group will receive a synbiotic composition (Lactobacillus acidophilus NCFM SD5221 10bilhões; Lactobacillus rhamnosus HN001 5675 SD 10 billion; Lactobacillus paracasei LPC SD 5275 - 37 10 billion; Bifidobacterium lactis SD 5674 HN0019 10 billion; Fructooligosaccharide 5.5 g) and the control group will receive 6 g of maltodextrin.The patients will received a synbiotic composition or maltodextrin for 15 days, twice times a day, after liver transplantation, when the patients are able to start feeding.

Patients will be evaluated for the occurrence of infections, need for additional antibiotics, length of hospital stay and mortality.

The Nutritional assessment will be carried out before and after surgery. All information will be collected and stored prospectively and the clinical trial will follow the instructions of the Consolidated Standards of Reporting Trials - CONSORT 2010.

Eligibility Criteria:
Inclusion Criteria:

* All adults patients who are undergoing liver transplantation

Exclusion Criteria:

* patients on parenteral nutrition
Shock Wave Therapy Versus Low Level Laser Therapy in Patients With Plantar Fasciitis

Both shock wave therapy and low level laser therapy in plantar fasciitis are effective in improvement of such cases without any side effects but there are no previously published studies on the use of shock wave therapy versus low level laser therapy in plantar fasciitis and, hence, evidence of its acceptability and effectiveness compared with each other remains to be established.

Plantar fasciitis is a result of degenerative irritation of the plantar fascia origin at the medial calcaneal tuberosity of the heel as well as the surrounding perifascial structures, it is a common problem accounting for approximately one million patient visits per year, it is often an overuse injury. As a result tight gastrocnemius, soleus, and/or other posterior leg muscles have also been commonly found in patients with this condition.

Shock wave therapy is thought to provide long lasting analgesia and stimulate the healing process, Low level laser therapy has been used to relieve pain caused by plantar fasciitis, also stretching of the shortened and contracted plantar flexors may positively influence an individual's functional activities of daily living and decrease the risk of injury.

Eligibility Criteria:
Inclusion Criteria:

1. Age ranges from 40-60 years old.
2. Both genders will be included.
3. Unilateral plantar fasciitis.
4. Duration of symptoms more than 4 weeks.
5. Positive Windlass test and negative Tinel and calcaneus squeeze tests.
6. Patients will be classified according to their BMI (18.5 - 24.9) kg/m2

Exclusion Criteria:

1. Open wound, infection in plantar surface of foot.
2. History of foot surgery.
3. History of trauma or fracture in foot or ankle.
4. Neuropathic pain as diabetes mellitus.
5. Peripheral vascular disease.
6. Calcaneal stress fracture or show evidence of a foreign body or tumor of the affected heel.
7. Previously suffered a rupture or surgery of the plantar fascia. Existing or prior osteomyelitis of the involved calcaneus.
Acitretin and Etanercept in Psoriasis

To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.

This study will include patients with moderate to severe psoriasis who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) and have not achieved PASI 75. They will be given acitretin 25 mg/day. The combined treatment will occur over 6 months. Subjects' progress will be assessed monthly, based on the improvement of their PASI and PGA scores.

Eligibility Criteria:
Inclusion Criteria:

* Adults (aged 18 to 80 years old) with moderate to severe psoriasis (defined as having a physician global assessment score of 3 \[moderate\] or higher) who are on etanercept 50 mg SQ once weekly and have not achieved PASI 75 after 12 weeks or more of treatment with etanercept
* All patients on etanercept have been tested for TB before initiation of etanercept

Exclusion Criteria:

* Patients \< 18 years old or \> 80 years old
* Patients who are not on etanercept 50 mg SQ once weekly
* Women of childbearing potential (Note: women of non-childbearing potential, meaning surgically sterile \[bilateral oophorectomy, hysterectomy, and/or bilateral tubal ligation\] or post-menopausal for at least 2 years, are eligible)
* Inability to understand consent or comply with study requirements
* Uncontrolled hypertriglyceridemia
* Patients with severely impaired hepatic function
* Patients without health insurance or who are not willing to pay out-of-pocket for etanercept and laboratory tests
* Systemic psoriasis therapies or PUVA within the past 2 weeks
* UVB or topical psoriasis therapies (other than emollients/moisturizers and OTC shampoos) within the past 1 week
* Patients with epilepsy or multiple sclerosis